
October 20-21, 2025
The Joseph B. Martin Conference Center
Biomarkers of Aging
2025 Conference
Join world-renown leaders defining and shaping the future
of aging biomarkers for longevity interventions
The Premier Conference on
Biomarkers of Aging for Longevity Interventions.
Anti-aging therapies are nearing the clinic - but without standardized, validated tools to measure aging, progress stalls. Our annual Conference brings together global leaders in geroscience to define and advance reliable biomarkers of aging, essential for evaluating the safety and impact of longevity interventions.
2025 Agenda
To be updated soon
2025 Speakers
-
Albert-Laszlo Barabasi, Ph.D.
NORTHEASTERN UNIVERSITY
Albert-László Barabási, is Distinguished Professor at Northeastern University and faculty at the Division of Network Medicine at Harvard Medical School. He is one of the founders of network medicine and his current research uncovers how complex networks—from genes to diseases—shape health and human longevity.
-
Michael Basson, Ph.D.
NATURE MEDICINE
Dr. Basson is a Senior Editor at Nature Medicine, where he handles manuscripts on aging, regenerative medicine, bioengineering and cardiovascular disease.
-
Evelyne Bischof, M.D.
SHEBA LONGEVITY CENTER
Prof. Evelyne Bischof, MD, is a specialist in internal medicine with a focus on Healthy Longevity Medicine and geroscience. She serves as Medical Director at the Sheba Longevity Center and holds professorships at Shanghai University of Medicine and Health Sciences and Tel Aviv University. She is also the Founding President of the Healthy Longevity Medicine Society (HLMS) and co-author of Longevity Education Hub.
-
Joe Betts-LaCroix, Ph.D.
RETRO BIO
Dr. Betts-LaCroix is the CEO of Retro Biosciences, which uses high-throughput, high-dimensional approaches to develop therapies for diseases driven by the biology of aging. His academic background spans Harvard, MIT, and Caltech and he invented over 100 patents & applications, found 2 prior companies (185 employees), spent 2 years as a part-time partner at Y Combinator, invested in & advised numerous biotechs, and published a Science paper in biophysics.
-
Gil Blander, Ph.D.
INSIDE TRACKER
Dr. Gil Blander is the founder of InsideTracker, a leading healthspan platform with over 100,000 users that leverages blood biomarkers, DNA, wearables, food tracking, and AI to deliver personalized health guidance. He hosts the Longevity by Design podcast and has a PhD in biology from the Weizmann Institute of Science, with postdoctoral research at MIT focused on aging and caloric restriction. Gil is passionate about translating longevity science into actionable tools that help people live longer, healthier lives.
-
Fei Chen, Ph.D.
BROAD INSTITUTE
Fei Chen, a core member of the Broad Institute and associate professor at Harvard, develops innovative tools integrating single-cell genomics with spatial and temporal analysis to uncover how and when cell types function within intact tissues. -
Andrea Cipriano, Ph.D.
STANFORD SCHOOL OF MEDICINE
Dr. Andrea Cipriano, faculty at the Stanford Stem Cell Institute and Department of Obstetrics and Gynecology, serves on the Biomarkers of Aging Consortium executive team where he advances immune aging biomarker validation and researches how chromatin changes impair T-cell function and how partial reprogramming can restore immune resilience.
-
Eileen M. Crimmins, Ph.D.
AARP CHAIR IN GERONTOLOGY
USC DAVIS SCHOOL OF GERONTOLOGYEileen Crimmins is the AARP Professor in the Davis School of Gerontology at the University of Southern California. Her research focuses on using biomarkers to explain population differences in aging health. She co directs an NIH sponsored Biomarker Network.
-
Luigi Ferrucci, M.D. Ph.D.
NATIONAL INSTITUTE OF AGING
Dr. Luigi Ferrucci, a geriatrician and epidemiologist, is Chief of the Longitudinal Studies Section at the NIA and Director of the Baltimore Longitudinal Study on Aging, focusing on the biological pathways of physical and cognitive decline in aging.
-
Kristen Fortney, Ph.D.
BIOAGE LABS
Kristen Fortney is the CEO & co-founder of BioAge, a clinical-stage biotechnology company harnessing the biology of human aging to develop new therapies for obesity and metabolic diseases. Her background is in aging biology and bioinformatics, with a PhD in Medical Biophysics from the University of Toronto, followed by postdoctoral training at Stanford. She serves as an advisor to multiple biotechnology companies. -
David Furman, Ph.D.
BUCK INSTITUTE
David Furman is Associate Professor and Director of the AI and Bioinformatics Core at the Buck Institute for Research on Aging and Head of the Stanford 1,000 Immunomes Project at Stanford University. His research leverages systems biology, artificial intelligence, and advanced computational approaches to elucidate the role of the immune system in human aging, functional decline, and age-related disease.
-
Vadim Gladyshev, Ph.D.
HARVARD MEDICAL SCHOOL
Dr. Vadim Gladyshev, professor of medicine at Brigham and Women’s Hospital and Harvard Medical School, is a National Academy of Sciences member whose research on aging, lifespan control, and rejuvenation has earned him NIH Pioneer, Transformative, and Eureka awards. -
David Glass, Ph.D.
REGENERON
David J. Glass, MD, is a VP of Research, overseeing a group focused on Aging and Age-associated Disorders, head of the Postdoctoral fellow program at Regeneron Pharmaceuticals, Inc, Senior Lecturer in the Department of Cell Biology at Harvard Medical School, and Adjunct Professor at Columbia University. He’s an elected fellow of AAAS and ASCI, the National Academy of Sciences, and co-author of more than 130 peer-reviewed research articles on cell signaling mechanisms in neuromuscular junction formation, skeletal muscle atrophy & hypertrophy, obesity, and mechanisms associated with aging.
-
Chiara Herzog Ph.D.
KING’S COLLEGE LONDON
Dr. Chiara Herzog, junior group leader at King’s College London and Executive Committee member of the Biomarkers of Aging Consortium, researches epigenetics and aging through non-invasive biomarkers and large-scale intervention studies on how lifestyle factors shape aging and health.
-
Steve Horvath, Ph.D.
ALTOS LABS
Dr. Steve Horvath, Principal Investigator at Altos Labs, is a leading researcher in biogerontology and epigenetic biomarkers of aging, renowned for developing the first epigenetic clocks and the WGCNA method, with a career spanning UCLA and numerous high-impact scientific contributions.
-
Jamie Justice, Ph.D.
XPRIZE FOUNDATION
Dr. Jamie Justice is the Executive VP Health Domain, Director of the $101M Healthspan Prize at XPRIZE Foundation, and Adjunct Professor in Internal Medicine at Wake Forest University School of Medicine (WFUSM). She was the recipient of the Jarrahi Research Scholars Fund in Geroscience Innovation, the 2022 Vincent Cristofalo Rising Star in Aging Research, and the 2022 NIA Nathan W Shock Awardee. Her training background at University of Colorado Boulder, academic research at WFUSM, and global leadership at XPRIZE advance translation of therapeutics to improve human healthspan and ovarian function.
-
Tommy Kaplan, Ph.D.
HEBREW UNIVERSITY
Tommy Kaplan is a Professor of Computer Science and Computational Biology at Hebrew University. His research focuses on biology of aging, genomics, DNA methylation, Machine Learning and cell-free DNA.
-
Guido Kroemer, M.D., Ph.D.
UNIVERSITE DE PARIS CITE
With over 1,700 scientific articles, including 72 in CNS journals—Cell (16), Nature (6), Nature Medicine (24), Science (18), and Science Translational Medicine (8), more than 450,000 citations and an h-index of 304, Guido Kroemer is Europe’s most cited biomedical researcher and the most cited worldwide in biology and biochemistry.
-
Jessica Lasky-Su, Sc.D.
HARVARD MEDICAL SCHOOL
Dr. Lasky-Su has been a leader in applying genetics, epigenetics, proteomics metabolomics, and antibody profiling to epidemiologic research, covering a wide range of chronic diseases across the entire life course. Much of her work has focused on chronic disease and longevity through the lens of integrative metabolomics. She has made broad contributions, with nearly 300 peer-reviewed publications spanning diverse disease and aging-related outcomes and exposures that influence health across the life course.
-
Dylan Livingston
ALLIANCE FOR LONGEVITY INITIATIVES
Dylan V. Livingston is the Founder/CEO of the Alliance for Longevity Initiatives. He was instrumental in the founding and growth of the Longevity Science Caucus in the House of Representatives, as well as the passage of SB 422 and SB 535 in Montana, which expands access to longevity medicine to patients.
-
Andrea B. Maier, M.D.
NATIONAL UNIVERSITY OF SINGAPORE
CHI LONGEVITY FOUNDER
Andrea Maier is Oon Chiew Seng Professor in Medicine, NUS Academy of Healthy Longevity, National University of Singapore and Professor of Gerontology, Human Movement Sciences VU Amsterdam. She is an authority in human cohort studies and randomized controlled trials (H index 85, i10 index 347), invited member and advisor of international academic and health policy committees and funding agencies (e.g., WHO), and past Founding President of the Healthy Longevity Medicine Society. In 2023, she co-founded the NUS Academy for Healthy Longevity to conduct, teach and disseminate Geroscience and Precision Geromedicine. -
JoAnn E. Manson, Ph.D.
HARVARD MEDICAL SCHOOL
JoAnn E. Manson, MD, MPH, DrPH, MACP, is Professor of Medicine and the Michael and Lee Bell Endowed Professor of Women’s Health at Harvard Medical School, Professor in the Department of Epidemiology, Harvard T.H. Chan School of Public Health, and Chief of the Division of Preventive Medicine at Brigham and Women's Hospital (BWH). She is a lead investigator on the VITamin D and OmegA-3 TriaL (VITAL); the COSMOS trial, and the Women’s Health Initiative, and studies interventions to reduce aging-related diseases, including heart disease, cognitive decline, and cancer, as well as related biomarkers of aging. She has received numerous honors and is one of the most highly cited researchers in the world.
-
Terrie E. Moffitt, Ph.D.
DUKE UNIVERSITY
Terrie Moffitt is the Nannerl O. Keohane University Professor of Psychology at Duke University, and Professor of Social Development at King’s College London. She is the PI of the team who developed DunedinPACE and is Associate Director of the Dunedin Longitudinal Study, which follows a 1972 birth cohort in New Zealand. In her spare time, she works on her poison-ivy farm in North Carolina.
-
Monty Montano, Ph.D.
AGING CELL
Dr. Monty Montano, Scientific Director of the Boston Pepper OAIC at Brigham and Women’s Hospital, Harvard Medical School faculty member, and Editor-in-Chief of Aging Cell and Executive Editor of Advanced Science, researches aging, musculoskeletal regeneration, and chronic infection, building on his PhD in Genetics from Stanford and authorship of Translational Biology in Medicine.
-
Mahdi Moqri, Ph.D., M.B.A
HARVARD MEDICAL SCHOOL
Mahdi Moqri is an Instructor in Aging Research at Harvard (Gladyshev Lab, Genetics) and Stanford (Snyder Lab, Genetics), and leading the executive committee of the Biomarkers of Aging Consortium.
-
Viviana Perez, Ph.D.
NATIONAL INSTITUTE ON AGING
Dr. Viviana Perez, with over 20 years of experience in aging biology spanning academia, industry, and leadership, is a former NIA program manager who rejoined the institute after serving at the Hevolution Foundation, building on her PhD training in Chile and postdoctoral research at the Barshop Institute.
-
Jesse Poganik, Ph.D.
HARVARD MEDICAL SCHOOL
Jesse Poganik is an Instructor in Medicine at Brigham and Women’s Hospital and Harvard Medical School. His research focuses on understanding the fundamental aspects of aging: the temporal dynamics of biological age, the inter-cellular and inter-tissue dynamics of aging. Jesse Poganik also serves on the Executive Committee of the Biomarkers of Aging Consortium.
-
Nathan Price, Ph.D.
BUCK INSTITUTE
Dr. Nathan Price is Professor and Co-Director of the Center for Human Healthspan at the Buck Institute for Research on Aging and Chief Scientific Officer of Thorne, a science-driven wellness company that serves 5 million+ customers and 47,000 health-care practitioners. In 2019, he was named one of the 10 Emerging Leaders in Health and Medicine by the National Academy of Medicine, and in 2021 he was appointed to the Board on Life Sciences of the National Academies of Sciences, Engineering, and Medicine..
-
Shigeo Horie, M.D., Ph.D.
JUNTENDO UNIVERSITY
Dr. Horie is Professor and Chair of Urology, Data Science and Informatics for Genetic Disorders, and Innovative Longevity Medicine at Juntendo University, Tokyo. He is internationally recognized for his contributions to men’s health, nephrology, and aging research, including pioneering clinical studies in autosomal dominant polycystic kidney disease. He leads the Japan Longevity Consortium, advancing translational research in biological age reversal and rejuvenation medicine.
-
Paola Sebastiani, Ph.D.
HARVARD MEDICAL SCHOOL
Paola Sebastiani, PhD, is director of the Center on Quantitative Methods and Data Science, associate director of the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine. She is a multidisciplinary biostatistician, with a track record of innovations in Bayesian statistics, machine learning and artificial intelligence, and analysis of genetics and genomic data. She is multiple PI of the Integrative longevity Omics and of the Long Life Family Study, and leader of the centenarian project in the Longevity Consortium.
-
Shai Shen-Orr, Ph.D.
TECHNION
Shai Shen-Orr is a Professor at the Technion-Israel Institute of Technology, co-CSO of the global non-profit the Human Immunome Project and Chief Scientist of CytoReason, a PharmaAI leader. He is the Director of the Zimin Institute for AI Solutions in Healthcare and the Technion Healthy Aging Institute. Shai develops novel analytics for studying the immune system—tools which he applies to study the drivers of immune variation, and their implications for Precision Medicine. The Human Immunome Project aims to map the diversity of the immune system across the globe to enable predictive outcomes and causal interpretation.
-
Alexey Terskih, Ph.D.
UNIVERSITY OF WESTERN AUSTRALIA
Alexey V. Terskikh is a Future Health Research & Innovation Distinguished Fellow, Head of the Chromatin and Ageing Laboratory at the Harry Perkins Institute and Professor at The University of Western Australia. He has a part-time position at the Scintillon Research Institute in San Diego, California. Alexey’s group discovered that patterns of epigenetic marks in the nucleus inform cellular identities and developed a novel technique: microscopic imaging of epigenetic landscapes (MIEL). Application of this technique to ageing, termed image-based chromatin and epigenetic age (ImAge), captures intrinsic age-related progressions (trajectories) of the spatial organisation of chromatin and epigenetic marks in single nuclei.
-
Sebastien Thuault, Ph.D.
NATURE AGING
Sebastien Thuault is the Chief Editor of Nature Aging, a peer-reviewed scientific journal that publishes research, reviews and opinion articles on aging and age-related diseases covering the life, health and social sciences. Dr Thuault holds a PhD in neuroscience and has been working in scientific publishing and communication for over 10 years. He was formerly an editor at Nature Neuroscience and Nature Communications and launched Nature Aging in 2021.
-
Wolfgang Wagner, M.D., Ph.D.
RWT AACHEN MEDICAL SCHOOL
Dr. Wagner is chair of the Institute for Stem Cell Biology at the Medical Faculty of RWTH Aachen University in Germany and co-founder of Cygenia GmbH, which provides services in the field of epigenetic analysis. His research focuses on DNA methylation changes during differentiation and, in particular, during the aging process, with the aim of gaining a better understanding of what drives epigenetic clocks and how they are coordinated.
-
Alex Zhavoronkov, Ph.D.
INSILICO MEDICINE
Alex Zhavoronkov, PhD, is the founder, CEO and CBO of Insilico Medicine, a leading clinical-stage biotechnology company developing next-generation generative artificial intelligence and automation platforms for drug discovery. Under his leadership, Insilico raised over $500 million, opened R&D centers in 8 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Since 2021, the company nominated more than 22 preclinical candidates, 10 reached clinical stage, and 1 program with a novel target and novel molecule completed Phase Iia in IPF with favorable safety, tolerability and encouraging dose-dependent efficacy.
-
Gavin Zhou, Ph.D.
REGEN BIO
Gavin Zhou is the CTO of Regenerative Bio, a longevity company driven by artificial intelligence. Founded in 2021 with the vision of "Health Equity - Empowering Everyone to Age Gracefully and Healthily", the company has developed "Organ-level aging clock" technology and applied it into their platform RevOrgan through precise measurements and effective interventions solutions.
2025 Conference Organizers
Chiara Herzog, Ph.D.
Executive Committee
Andrea Cipriano, Ph.D.
Executive Committee
Nicholas C. Fiorenza
Core Team
Ludger Goeminne, Ph.D.
Core Team
Luisa Georgiana Baca, Ph.D.
Core Team
Allison Deuttmann
Executive Committee
Jesse Poganik, Ph.D.
Executive Co-Director
Vadim Gladyshev, Ph.D.
Conference Chair
Dane Gobel
Executive Committee
Mahdi Moqri, Ph.D., M.B.A.
Executive Co-Director
2025 Sponsors & Media Partners
Limited sponsorship opportunities available. Get in touch with Nicholas Fiorenza to learn about availabilities.
2024 Highlights
Nearly 500 attendees from over 30 countries and 28 US States attended, with two days of cutting-edge programming featuring 48 talks by leading scientists, industry experts, and top poster presenters, sharing insights to support the entire field. Over 50 flash talks and 100 posters showcased research from prestigious universities and life sciences companies.
Biomarkers of Aging Challenge Phase I and Phase II Winners Announced
The Challenge aims to generate the most accurate predictive models for aging biomarkers, including mortality and multi-morbidity. Phase I and II winners were awarded a total of $100,000 USD.
The Longevity Study Pilot Launched
The Longevity Study is a longitudinal multi-modal deep-profiling human health study, dedicated to understanding how aging affects us at molecular and functional level. This study contributes substantially to our understanding of how our bodies change as we age and which molecular changes drive functional decline. We reached several major milestones: 1) launching our Study and 2) achieving our target of 100 participants and collected 300+ samples.
Sponsorship Impact
With the support of 30 mission-aligned sponsors and partners, we supported meaningful collaborations and long-term ROI for all involved.
Community Momentum
New connections and collaborations formed, lasting friendships developed, and familiar faces reconnected, all sharing a passion for advancing the science of longevity.
Sign up for updates and access to early-bird tickets: agingconsortium.org/#join
Inquiries? Like to sponsor? Get in touch with the team: community@agingconsortium.org
Thank you 2024 Speakers!
Austin Argentieri, PhD
Harvard University
Omar Abudayyeh, PhD
Harvard University
Nir Barzilai, MD
Albert Einstein
College of Medicine
Ed Boyden, PhD
MIT
Andrew Brack, PhD
ARPA-H
Jason Buenrostro, PhD
Harvard University
Luigi Ferrucci, PhD
National Institute of Aging
Eric Morgen, MD
BioAge Labs
David Furman, PhD
Buck Institute
Vadim Gladyshev, PhD
Harvard University
Christin Glorioso,
MD, PhD
NeuroAge Therapeutics
Dane Gobel
Methuselah Foundation
Dave Gobel
Methuselah Foundation
Jonathan Gootenberg, PhD
Harvard University
Sara Hägg, PhD
Karolinska Institutet
Chiara Herzog, PhD
University of Innsbruck
Steve Horvath, PhD
Altos Labs
Jamie Justice, PhD
XPRIZE Healthspan
Gordan Lauc, PhD
University of Zagreb
Xiao-Jun Ma, PhD
Alamar Biosciences
Raymond H. Mak, MD
Harvard University
Andrea Maier, MD, PhD
NUS
Riccardo E. Marioni, PhD
University of Edinburgh
Mahdi Moqri, PhD, MBA
Harvard University
Seth Paulson
Methuselah Foundation
Viviana Perez, PhD
NIH
Jesse Poganik, PhD
Harvard University
Julian Reinhard
Evotec
Björn Schumacher, PhD
University of Cologne
Vittorio Sebastiano, PhD
Stanford University
Raghav Sehgal, PhD
Yale University
David Sinclair, PhD
Harvard University
Michael Snyder, PhD
Stanford University
Alexandra Stolzing, PhD
Loughborough University
Gavin Zhou, PhD
Regen Bio
Waylon Hastings, PhD
Texas A&M
John Earls, PhD
Buck Institute
George Church, PhD
Wyss Institute
Jessica Lasky-Su, PhD
Harvard University
Jessica Kasamoto, MSc
Yale University
Alexander Tyshkovskiy, PhD
Harvard University
John Tsang, PhD
Yale University
Tina Woods, MBA
Collider Health
Eric Verdin, MD
Buck Institute
Tony Wyss-Coray, PhD
Stanford University
Kejun Albert Ying, PhD
Harvard University
Lynne Cox, PhD
Wellcome Leap
Christian Behrens,
PhD, RD
Bayer
Revisit our 2024 Day 2 Talks
Day 2 focused on the translational and clinical dimensions of the field, fostering discussions and collaboration between scientists, clinicians, and entrepreneurs.
2024 Media Coverage
Check out news articles highlighting our 2024 Conference. Click on the image to read the article.
